|Bid||12.80 x 1200|
|Ask||12.90 x 3200|
|Day's Range||12.52 - 13.32|
|52 Week Range||4.77 - 22.39|
|Beta (3Y Monthly)||3.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 7, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.42|
Arrowhead Pharmaceuticals Inc. today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-ANG3, an RNAi-based investigational medicine targeting angiopoietin like protein 3 being developed for the treatment of dyslipidemias and metabolic diseases.
Arrowhead Pharmaceuticals Inc. today announced that it has filed an application for approval to begin a Phase 1 clinical trial of ARO-APOC3, an RNAi-based investigational medicine targeting Apolipoprotein C-III being developed for the treatment of hypertriglyceridemia.
Arrowhead Pharmaceuticals Inc. (ARWR) today announced that as an inducement to entering into employment with the Company, on December 7, 2018, the Board of Directors approved "inducement" grants to 3 new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The option grants entitle the employees, in aggregate, to purchase up to 47,000 shares of common stock. The strike price of options is set at an exercise price per share of $13.66, the last reported closing price of the Company's common stock on December 10, 2018, the date of grant, except for certain shares which will be priced at the last reported closing price of the Company’s common stock on the date of hire of one new employee, anticipated to be within 60 days of the date of the approval.
On December 12, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.19, an ~11.53% rise from its previous day’s close of $13.62. Arrowhead Pharmaceuticals stock rose from $3.68 at the close of market on December 29, 2017, to reach $15.19 at the close of market on December 12, reflecting a ~313% year-to-date rise.
NEW YORK, NY / ACCESSWIRE / December 12, 2018 / U.S. equities finished lower on Tuesday after bouncing between the red and green territory. The stocks gained more than 1% across the board on improving ...
The company announced two late-breaking poster presentations at an important industry meeting -- and impressed with early-stage data.
Johnson & Johnson (JNJ) inks a global deal with Europe's argenx to jointly develop and globally commercialize the latter's prospective antibody, cusatuzumab.
Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it will host a webcast and conference call on December 11, 2018, at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September 30, 2018. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 6744427. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 6744427.
Arrowhead Pharmaceuticals stock rose from $3.68 at the close of market on December 29, 2017, to $12.95 at the close of market on November 21, 2018, a ~252% rise year-to-date. On November 21, Arrowhead Pharmaceuticals closed at $12.95, ~42% below the 52-week high of $22.39 it reached on September 6. Arrowhead Pharmaceuticals hit its 52-week low of $3.01 on December 13, 2017.
PASADENA, Calif.-- -- Three monthly doses of 300 mg ARO-AAT led to reductions in serum alpha-1 antitrypsin to below the level of quantitation in 100% of subjects Reductions were sustained for greater than 14 weeks indicating that quarterly or less frequent dosing appears feasible Single and multiple doses of ARO-AAT appear to be well-tolerated at all doses tested Arrowhead Pharmaceuticals Inc. today ...
- Mean HBsAg reduction of -1.9 Log10 with a range of -1.3 Log10 to -3.8 Log10
The company de-risked the development of its potential blockbuster hepatitis B drug for a cool $250 million. Investors thought the price was too low.
Arrowhead Pharmaceuticals Inc. today announced that it is scheduled to present at the following upcoming events:
Arrowhead Pharmaceuticals Inc. today announced that the license agreement and research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and the stock purchase agreement between Arrowhead and Johnson & Johnson Innovation – JJDC, Inc., have closed, following termination of the waiting period under ...
Arrowhead Pharmaceuticals Inc. (ARWR) is hosting a Research & Development (R&D) Day today in New York to discuss its emerging pipeline of RNAi therapeutics that leverage the Company’s proprietary Targeted RNAi Molecule (TRiM™) platform. In addition to senior members of the Arrowhead team, the R&D Day includes, Ira J. Goldberg, M.D., Bronfman Professor of Medicine, Chief of the Division of Endocrinology, Diabetes, and Metabolism, New York University Langone School of Medicine. A live and archived webcast of the event, with slides, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.